=> s l2
L3 7 L2

=> d abs bib hitstr 1-7

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
AB The present invention provides IRM conjugates that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety in which the covalent link does not depend on UV irradiation The IRM is an imidazoquinoline amine, tetrahydroimidazoquinoline amine, imidazopyridine amine, 1,2-bridged imidazopyridine amine, 6,7-cycloalkylimidazopyridine amine, imidazonaphthyridine amine, tetrahydroimidazonaphthyridine amine, oxazoloquinoline amine, thiazoloquinoline amine, oxazolopyridine amine, thiazolopyridine amine, etc. These IRM compds. appear to act through TLRs to induce selected cytokine biosynthesis and/or co-stimulatory mols. and increase antigen-presenting capacity. The IRM conjugates are directed against e.g. tumor, viral infection, allergy, autoimmune disease ans as vaccine adjuvant.
AN 2007:999273 CAPLUS
DN 147:321284
TI Antibody or antigen conjugated with immune response modifier for therapeutic use
IN Stoermer, Doris; Griesgraber, George W.; Mendoza, James D.; Bonk, Jason D.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007100634	A2	20070907	WO 2007-US4673	20070221
	WO 2007100634	A3	20071025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1988896	A2	20081112	EP 2007-751438	20070221
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 20090035323	A1	20090205	US 2008-280472	20080822
PRAI	US 2006-775468P	P	20060222		
	WO 2007-US4673	W	20070221		

IT 948029-59-2P
RL: MOA (Modifier or additive use); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(antibody or antigen conjugated with immune response modifier for therapeutic use)

RN 948029-59-2 CAPLUS

CN Propanamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-3-mercapto- (CA INDEX NAME)



IT 948029-58-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(antibody or antigen conjugated with immune response modifier for therapeutic use)

RN 948029-58-1 CAPLUS

CN Propanamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-3-[(triphenylmethyl)thio]- (CA INDEX NAME)



L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides immunomodulatory compns. include an immune response modifier moiety coupled to a targeting moiety. In another aspect, the invention provides methods of providing targeted delivery of an IRM for formula I, generating a localized immune response, and treating a condition in a subject. Generally, the methods include administering to the subject an immunomodulatory composition that includes an immune response modifier moiety coupled to a targeting moiety that recognizes a delivery target. Compds. of formula I wherein R1 is a linker group; R2 is H, alkyl, alkenyl, (un)substituted (hetero)aryl, etc.; R3 and R4 are independently H, halo, alkyl, alkenyl, O-alkyl, S-alkyl, etc.; are claimed. Example compound II was prepared by amidation of 6-(carbobenzyloxyamino)caproic acid with 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine; the resulting benzyl 6-[[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]1,1-dimethylethyl]amino]-6-oxohexylcarbamate underwent hydrogenation followed by coupling with 3,3-dithiodipropionic acid to give the corresponding disulfide dimer which underwent cleavage to give compound II. All the invention compds. were tested for their ability to generate a localized immune response.

AN 2006:888349 CAPLUS

DN 145:293058

TI Imidazo[4,5-c]quinoline derivatives and their preparation, immunomodulatory compositions and methods for targeted delivery of immune response modifiers

IN Alkan, Sefik; Kieper, William C.; Vasilakos, John P.; Bonk, Jason D.; Griesgraber, George W.; Lipson, Kenneth E.; Liu, Jie J.; Mendoza, James D.; Stoermer, Doris; Wightman, Paul D.; Jing, Naiyong; Schultz, William J.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 83pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006091720	A2	20060831	WO 2006-US6387	20060223
	WO 2006091720	A3	20070823		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20060009482	A1	20060112	US 2005-220235	20050906

AU 2006216669 A1 20060831 AU 2006-216669 20060223
CA 2598144 A1 20060831 CA 2006-2598144 20060223
EP 1850850 A2 20071107 EP 2006-735874 20060223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
JP 2008531580 T 20080814 JP 2007-557149 20060223
PRAI US 2005-655713P P 20050223
US 2005-220235 A2 20050906
US 2000-254229P P 20001208
US 2001-13193 A1 20011206
WO 2006-US6387 W 20060223
OS CASREACT 145:293058; MARPAT 145:293058
IT 895522-08-4P 895522-09-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazoquinoline derivs. and their immunomodulatory compns. and methods for targeted delivery of immune response modifiers useful in treatment of diseases)
RN 895522-08-4 CAPLUS
CN Benzamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxy- (CA INDEX NAME)



RN 895522-09-5 CAPLUS
CN Benzamide, N-[6-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxy- (CA INDEX NAME)



IT 812631-90-6 850069-15-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of imidazoquinoline derivs. and their immunomodulatory compns. and methods for targeted delivery of immune response modifiers useful in treatment of diseases)
RN 812631-90-6 CAPLUS
CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 850069-15-7 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-7-[(6-aminohexyl)oxy]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (CA INDEX NAME)



L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I



II

AB The present invention provides immunomodulatory compns. include an immune response modifier (IRM) moiety coupled to a targeting moiety. In another aspect, the invention provides methods of providing targeted delivery of an IRM, generating a localized immune response, and treating a condition in a subject. Generally, the methods include administering to the subject an immunomodulatory composition that includes an immune response modifier moiety coupled to a targeting moiety that recognizes a delivery target. The IRM moiety has general formula I (wherein R1 is a linker group, R2 = H, alkyl, alkenyl, etc.; R3 and R4 = H, halo, alkyl, etc., or taken together are part of a fused ring). The preparation of the IRM compds. is exemplified. For example, II was prepared in 4 steps from an initial reaction of 6-(carbobenzyloxyamino)caproic acid and 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-4-amine. II was subsequently conjugated to human anti-CD20 antibody using

antibodies modified with heterobifunctional crosslinkers.
AN 2006:636837 CAPLUS
DN 145:103679
TI Preparation of small molecule immune response modifiers and conjugation to a targeting moiety
IN Alkan, Sefik; Kieper, William C.; Vasilakos, John P.; Bonk, Jason D.; Griesgraber, George W.; Lipson, Kenneth E.; Liu, Jie J.; Mendoza, James D.; Stoermer, Doris; Wightman, Paul D.; Jing, Naiyong; Schultz, William J.
PA 3M Innovative Properties Company, USA
SO U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 220,235.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060142202	A1	20060629	US 2006-360071	20060223
	US 20020110840	A1	20020815	US 2001-13193	20011206
	US 20060009482	A1	20060112	US 2005-220235	20050906
PRAI	US 2000-254229P	P	20001208		
	US 2001-13193	B1	20011206		
	US 2005-220235	A2	20050906		

OS CASREACT 145:103679; MARPAT 145:103679
IT 895522-08-4P 895522-09-5P,
N-[6-[[4-Amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxybenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of small mol. immune response modifiers and coupling to a targeting moiety)
RN 895522-08-4 CAPLUS
CN Benzamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxy- (CA INDEX NAME)



RN 895522-09-5 CAPLUS
CN Benzamide, N-[6-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-

imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxy- (CA INDEX NAME)



IT 895522-08-4DP, conjugates with antibodies 895522-09-5DP, N-[6-[[4-Amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxybenzamide, conjugates with antibodies
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of small mol. immune response modifiers and coupling to a targeting moiety)

RN 895522-08-4 CAPLUS

CN Benzamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxy- (CA INDEX NAME)



RN 895522-09-5 CAPLUS

CN Benzamide, N-[6-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-4-azido-2-hydroxy- (CA INDEX NAME)



IT 812631-90-6, N-[2-[4-Amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide
850069-15-7, N-[4-[4-Amino-7-[(6-aminohexyl)oxy]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of small mol. immune response modifiers and coupling to a targeting moiety)

RN 812631-90-6 CAPLUS
CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 850069-15-7 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-7-[(6-aminohexyl)oxy]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (CA INDEX NAME)



L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
GI



AB A soluble immune response modifier (IRM)-polymer complex, prepns., and methods of use, wherein the soluble IRM-polymer complex includes one or more IRM compds. attached (e.g., covalently attached) to a polymer (e.g., an alkylene oxide-containing polymer) are disclosed. For example, I as an IRM was prepared and conjugated with PEG derivs. such as methoxypolyethylene glycol succinimidylpropionate. An in-vitro human blood cell system was used to assess cytokine induction of the IRM conjugates.
AN 2005:1242319 CAPLUS
DN 144:6790
TI Preparation of imidazoquinoline amine derivative conjugates with PEG derivatives for delivery of immune response modifiers
IN Zarraga, Isidro Angelo E.; Stoesz, James D.; Ortiz, Ronnie
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005110013	A2	20051124	WO 2005-US11997	20050408
WO 2005110013	A3	20060316		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2005244260	A1	20051124	AU 2005-244260	20050408
CA	2562283	A1	20051124	CA 2005-2562283	20050408
EP	1735010	A2	20061227	EP 2005-778021	20050408
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP	2007532572	T	20071115	JP 2007-507539	20050408
US	20070166384	A1	20070719	US 2006-599730	20061006
IN	2006CN03736	A	20070615	IN 2006-CN3736	20061009
PRAI US	2004-560862P	P	20040409		
US	2004-617196P	P	20041008		
WO	2005-US11997	W	20050408		

OS CASREACT 144:6790

IT 812631-90-6DP, polyethylene glycol supported 869966-54-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazoquinoline amine derivative conjugates with PEG derivs.
for delivery of immune response modifiers)

RN 812631-90-6 CAPLUS

CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 869966-54-1 CAPLUS

CN Poly(oxy-1,2-ethanediyl), α-[3-[[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]amino]-3-oxopropyl]-ω-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 812631-90-6P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazoquinoline amine derivative conjugates with PEG derivs.
for delivery of immune response modifiers)
RN 812631-90-6 CAPLUS
CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



IT 812631-99-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazoquinoline amine derivative conjugates with PEG derivs.
for delivery of immune response modifiers)
RN 812631-99-5 CAPLUS
CN Carbamic acid, [6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I II

AB The title imidazoquinolines with an alkoxy substituent at the 6-, 7-, 8- or 9-position [I; R = alkyl, alkoxy, OH, etc.; n = 0-1; R1, R2 = H, non-interfering substituents; R3 = ZYR4, ZHet, etc. (Z = alkylene, alkenylene, and alkynylene optionally interrupted with one or more O groups; Y = S, SO, SO2, (un)substituted SO2NH, etc.; R4 = H, alkyl, aryl, etc.; Het = (un)substituted heterocyclyl)], useful as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic (no specific biol. data given), were prepared E.g., a multi-step synthesis of II, was given. Pharmaceutical compns. containing the compds. I are disclosed.

AN 2005:316318 CAPLUS

DN 142:392406

TI Preparation of alkoxy substituted imidazoquinolines as immunomodulators

IN Lindstrom, Kyle J.; Merrill, Bryon A.; Haraldson, Chad A.; Rice, Michael J.; Kshirsagar, Tushar A.; Heppner, Philip D.; Wurst, Joshua R.; Niwas, Shri; Johannessen, Sarah C.

PA 3M Innovative Properties Co., USA

SO PCT Int. Appl., 386 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005032484	A2	20050414	WO 2004-US32616	20041001
	WO 2005032484	A3	20050630		
	WO 2005032484	A9	20060518		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004278014	A1	20050414	AU 2004-278014	20041001
	CA 2540541	A1	20050414	CA 2004-2540541	20041001
	EP 1673087	A2	20060628	EP 2004-794092	20041001
	R: AT, BE, CH, LI, CY, BG, CZ				
	BR 2004014856	A	20061121	BR 2004-14856	20041001

	CN 1897948	A	20070117	CN 2004-80036217	20041001
	JP 2007507542	T	20070329	JP 2006-534221	20041001
	SG 149828	A1	20090227	SG 2009-236	20041001
	NZ 546273	A	20090531	NZ 2004-546273	20041001
	US 20070060754	A1	20070315	US 2006-595230	20060328
	MX 2006003705	A	20060620	MX 2006-3705	20060331
	IN 2006CN01139	A	20070831	IN 2006-CN1139	20060403
	KR 2006118453	A	20061123	KR 2006-708497	20060502
	ZA 2006003474	A	20080528	ZA 2006-3474	20060502
PRAI	US 2003-508634P	P	20031003		
	WO 2004-US32616	W	20041001		

OS CASREACT 142:392406; MARPAT 142:392406

IT 850057-42-0P 850057-43-1P 850057-44-2P
850057-45-3P 850057-46-4P 850057-47-5P
850063-72-8P 850063-73-9P 850063-74-0P
850063-75-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkoxy substituted imidazoquinolines as immunomodulators)

RN 850057-42-0 CAPLUS

CN Methanesulfonamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (CA INDEX NAME)



RN 850057-43-1 CAPLUS

CN Acetamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (CA INDEX NAME)



RN 850057-44-2 CAPLUS
CN Methanesulfonamide, N-[6-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (CA INDEX NAME)



RN 850057-45-3 CAPLUS
CN Acetamide, N-[6-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (CA INDEX NAME)



RN 850057-46-4 CAPLUS

CN Acetamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[[6-[(methylsulfonyl)amino]hexyl]oxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 850057-47-5 CAPLUS
CN Acetamide, N-[2-[7-[[6-(acetylamino)hexyl]oxy]-4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 850063-72-8 CAPLUS
CN Acetamide, N-[2-[4-amino-2-(ethoxymethyl)-7-[[6-[[[(1-methylethyl)amino]thioxomethyl]amino]hexyl]oxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 850063-73-9 CAPLUS
CN Urea, N-[2-[4-amino-2-(ethoxymethyl)-7-[[6-[[[(1-methylethyl)amino]carbonyl]amino]hexyl]oxy]-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 850063-74-0 CAPLUS
CN Acetamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (CA INDEX NAME)



RN 850063-75-1 CAPLUS
CN Methanesulfonamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]- (CA INDEX NAME)



IT 812631-90-6P 850069-14-6P 850069-15-7P
850069-18-0P 850069-19-1P 850069-33-9P
850069-34-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkoxy substituted imidazoquinolines as immunomodulators)
RN 812631-90-6 CAPLUS
CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 850069-14-6 CAPLUS
CN Carbamic acid, [6-[[4-amino-1-[4-[(methylsulfonyl)amino]butyl]-2-propyl-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850069-15-7 CAPLUS
CN Methanesulfonamide, N-[4-[4-amino-7-[(6-aminohexyl)oxy]-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl]butyl]- (CA INDEX NAME)



RN 850069-18-0 CAPLUS
CN Carbamic acid, [6-[[1-[2-(acetylamino)-2-methylpropyl]-4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850069-19-1 CAPLUS
CN Acetamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 850069-33-9 CAPLUS
CN Carbamic acid, [6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850069-34-0 CAPLUS
CN Urea, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
AB Pharmaceutical formulations in an aqueous (preferably, sprayable) formulation including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. In one embodiment, the aqueous formulations are advantageous for treatment and/or prevention of allergic rhinitis, viral infections, sinusitis, and asthma. For example, N-[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]methanesulfonamide (IRM 1) was prepared as a 0.375% aqueous solution capable of being nasally administered via a spray pump. The solution contained IRM 1 0.375%, CM-cellulose sodium 0.1%, benzalkonium chloride 0.02%, disodium EDTA 0.1%, L-lactic acid 1.53%, PEG 400 15%, 1N NaOH as needed for pH 4.0, and water to 100%. The IRM 1 solution (50 μL) administered to rats once 4 h before infection with humanized, non-lethal influenza virus, almost completely suppressed the virus. titer.
AN 2005:160991 CAPLUS
DN 142:246181
TI Formulations containing an amine-based immune response modifier
IN Hammerbeck, David M.; Guy, Cynthia A.; Leung, Suzanne S.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016275	A2	20050224	WO 2004-US25277	20040805
	WO 2005016275	A3	20050414		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004264336	A1	20050224	AU 2004-264336	20040805
CA	2534313	A1	20050224	CA 2004-2534313	20040805
US	20050070460	A1	20050331	US 2004-911800	20040805
EP	1651190	A2	20060503	EP 2004-780166	20040805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP	2007501252	T	20070125	JP 2006-522714	20040805
US	20070292456	A1	20071220	US 2006-595049	20060118
PRAI US	2003-493109P	P	20030805		
WO	2004-US25277	W	20040805		

IT 845638-56-4 845638-57-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (solns. containing amine-based immunomodulators)

RN 845638-56-4 CAPLUS

CN Methanesulfonamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-6-yl]oxy]hexyl]- (CA INDEX NAME)



RN 845638-57-5 CAPLUS

CN Acetamide, N-[6-[[4-amino-2-(ethoxymethyl)-1-[2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-6-yl]oxy]hexyl]- (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
GI



I

AB The present invention provides immune response modifiers (IRMs) associated with (typically, attached to, and preferably, covalently attached to) macromol. support materials. The IRM compds. in such IRM-support complexes retain biol. activity. Such attachment of an IRM to a macromol. support material provides for the localized biol. activity of the IRM. The IRM I was prepared and IRMs were linked to such carriers as avidin beads, gold particles, silica nanoparticles, and polymers.
AN 2004:1126841 CAPLUS
DN 142:79920
TI Delivery of immune response modifier compounds
IN Wightman, Paul D.; Zarraga, Isidro Angelo E.; Jing, Naiyong; Liu, Jie J.
PA USA
SO U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 640,904.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040258698	A1	20041223	US 2004-821335	20040409
	US 7427629	B2	20080923	US 2003-640904	20030814
	US 20040091491	A1	20040513		
PRAI	US 2003-462140P	P	20030410		
	US 2003-640904	A2	20030814		
	US 2003-515256P	P	20031029		
	US 2004-545424P	P	20040218		
	US 2004-545542P	P	20040218		
	US 2002-403846P	P	20020815		

IT 812631-90-6P 812631-99-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(delivery of immune response modifier compds.)

RN 812631-90-6 CAPLUS
CN Methanesulfonamide, N-[2-[4-amino-7-[(6-aminohexyl)oxy]-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl]- (CA INDEX NAME)



RN 812631-99-5 CAPLUS
CN Carbamic acid, [6-[[4-amino-2-(ethoxymethyl)-1-[2-methyl-2-[(methylsulfonyl)amino]propyl]-1H-imidazo[4,5-c]quinolin-7-yl]oxy]hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)